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Dysregulation of fatty acid metabolism is important in
the pathogenesis of type 2 diabetes. Peroxisome prolif-
erator–activated receptor (PPAR) is a master regula-
tor of fatty acid catabolism, and PPAR activators delay
the onset of type 2 diabetes. We examined association
between three PPAR gene polymorphisms (an A3C
variant in intron 1, the L162V variant, and the intron 7
G3C variant) and age at diagnosis of type 2 diabetes in
912 Caucasian type 2 diabetic subjects. Individually,
PPAR gene variants did not inﬂuence age at diagnosis,
but in combination, the rare alleles of both the intron 1
A3C( P < 0.001) and intron 7 G3C( P  0.025)
variants synergistically lowered age at diagnosis (inter-
action P < 0.001). Overall, the PPAR haplotype signﬁ-
cantly inﬂuenced age at diagnosis (P  0.027), with the
C-L-C and C-V-C haplotypes (intron 1–L162V–intron 7)
accelerating onset of diabetes by 5.9 (P  0.02) and 10
(P  0.03) years, respectively, as compared with the
common A-L-G haplotype, and was associated with an
odds ratio for early-onset diabetes (age at diagnosis
<45 years) of 3.75 (95% CI 1.65–8.56, P  0.002).
Intron 1 C-allele carriers also progressed more rapidly
to insulin monotherapy (AA 9.4  1.5 and AC  CC
5.3  1.1 years, P  0.002). These data indicate that
PPAR gene variation inﬂuences the onset and progres-
sion of type 2 diabetes. Diabetes 54:582–586, 2005
T
he etiology of type 2 diabetes involves the pro-
gressive development of insulin resistance in
skeletal muscle and culminates in pancreatic
-cell failure. Fatty acids contribute to the devel-
opment and progression of type 2 diabetes. Increased fatty
acid concentrations reduce skeletal muscle glucose up-
take and oxidation, stimulate hepatic gluconeogenesis
while inhibiting insulin suppression of gluconeogenesis,
and inhibit insulin production and glucose-stimulated in-
sulin secretion in pancreatic -cells (rev. in 1). Increased
fasting plasma fatty acid concentrations predict the dete-
rioration of glucose tolerance (2) and are a risk factor for
the development of type 2 diabetes (3).
Peroxisome proliferator–activated receptor (PPAR) is
a member of the nuclear hormone receptor superfamily of
ligand-regulated transcription factors for which ligands
include long-chain fatty acids, eicosanoids, and the ﬁbrate
class of lipid-lowering drugs (4). PPAR is expressed at
high levels in tissues that catabolize fatty acids, notably
liver, skeletal muscle, and heart, and at lower levels in
other tissues, including pancreas (5). PPAR is a master
regulator of fatty acid utilization (6), and activation of
PPAR causes a dramatic lowering of plasma, hepatic, and
intramuscular triglycerides (7). In rodent models of type 2
diabetes, administration of PPAR agonists reduces adi-
posity, normalizes fasting plasma glucose and insulin
levels, and improves insulin suppresson of endogeneous
glucose production (8–10). Furthermore, insulin secretion
and pancreatic hypertrophy and degeneration were im-
proved by PPAR activation (9,10). Recently, bezaﬁbrate
was shown to reduce the incidence and delay the onset of
type 2 diabetes, indicating that such effects may also occur
in humans (11).
These data indicate that PPAR acts pleiotropically to
ameliorate insulin resistance in the major cell types in-
volved in the pathogenesis of type 2 diabetes. Variation in
the PPAR gene inﬂuences plasma lipid levels (12,13),
cardiac growth (14), and risk of coronary artery disease
(15). We therefore examined association between varia-
tion in the PPAR gene and age at diagnosis (as a
surrogate for age of onset) and progression to type 2
diabetes in Caucasian type 2 diabetic participants in the
University College Diabetes and Cardiovascular Study
(UDACS) (16) and Ealing Diabetic Study of Coagulation
(EDSC).
RESEARCH DESIGN AND METHODS
European type 2 diabetic subjects were selected from two studies, UDACS
(16) and EDSC. UDACS and EDSC subjects were recruited consecutively from
the diabetes clinics at University College London Hospital and Ealing Hospi-
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582 DIABETES, VOL. 54, FEBRUARY 2005tal, respectively. Patients completed a questionnaire with details of age,
ethnicity, smoking habit, fasting status, duration of diabetes, family history of
diabetes, history of heart attack or stroke, current medication, and other
clinical details. Blood was collected for plasma and DNA analysis. BMI, blood
pressure, glucose, HbA1c, cholesterol, HDL, LDL, triglyceride, urea, creatinine,
albumin-to-creatinine ratio, potassium, and proteinuria were measured. All
patients had type 2 diabetes according to World Health Organization criteria
(17). No subjects requiring renal dialysis were recruited. Ethical approval was
obtained from University College London/University College London Hospital
and Ealing Hospital ethics committees and from data protection at University
College London. Middle-aged U.K. men (50–61 years, mean age 56.1  3.5
years) participating in the Second Northwick Park Heart Study were used as
a population-based sample for comparison of allele and haplotype frequencies
(15).
Genotyping. The intron 1 A/C variant (refsnp 135539) was genotyped using
forward primer CCAGGGGGAGGAAAGAGTGAA and reverse primer GCCAC
AACTAAGCAGGCAGTG to generate a product of 210 bp, which, when
digested with HinfI, gave products of 148 and 62 bp in the presence of the
C-allele. The L162V (refsnp 1800206) and intron 7 G/C (refsnp 4253778)
variants were genotyped as previously described (15).
Statistical analysis. Statistical analysis was performed by univariate ANOVA
and linear regression using SPSS (version 12; SPSS, Chicago, IL). Factors and
covariates, together with all two-way interactions, were entered into the
statistical model and removed in a stepwise manner until a parsimonious
model containing only factors or interactions that were statistically signiﬁcant
was obtained. Mean age at diagnosis, adjusted for family history of diabetes,
sex, and smoking, was generated by calculating residuals and adding to the
overall mean value. Haplotype frequencies and effects were determined using
THESIAS (18). Smoking status and BMI at diagnosis were not available;
therefore, measures at recruitment were used. BMI, triglycerides, and dura-
tion of diabetes before insulin treatment were log10 transformed to normalize
distribution. The three V162 allele homozygotes were combined with V162
allele carriers in all analyses. Data are shown as means  SE, and a P value
of 0.05 was considered statistically signiﬁcant.
RESULTS
The clinical characteristics of type 2 diabetic subjects are
shown in Table 1. The intron 1 A3C variant is situated
12.5 kb 3 of the site of transcriptional initiation of the
PPAR gene, 55 kb 5 of L162V, and 71 kb 5 of the intron
7G 3C variant. Rare allele frequencies were intron 1
A3C 0.404 (95% CI 0.381–0.427), L162V 0.064 (0.053–
0.076), and intron 7 G3C 0.187 (0.169–0.205). The intron
1A 3C variant was selected due to its rare allele fre-
quency and close proximity to the 5 end of the PPAR
gene, whereas the L162V and intron 7 G3C variants have
previously shown positive results in association studies
(12–15). No other PPAR variants were examined. Geno-
type distributions were in Hardy-Weinberg equilibrium and
were not different between the two study centers. Allele
frequencies were not signiﬁcantly different between type 2
diabetic subjects and those previously reported in healthy
U.K. middle-aged men (15). All three variants were in
linkage disequilibrium (intron 1–L162V D0.57, P 
0.0001; intron 1–intron 7 D0.46, P  2.6  10
8;
L162V–intron 7 D0.58, P  2.7  10
23).
Individually, PPAR gene variants did not inﬂuence age
at diagnosis when examined by ANOVA (Table 2), but
when examined in combination, both the intron 1 A3C
(P 	 0.001) and intron 7 G3C( P  0.025) variants
signiﬁcantly inﬂuenced age at diagnosis and showed a
signiﬁcant interaction (intron 1  intron 7 interaction, P 	
0.001), acting synergistically to lower age at diagnosis
(Table 3). In multivariate linear regression, sex (P 
0.001), currently smoking (P  0.026), family history of
diabetes (P 	 0.001), intron 1 genotype (P  0.001), intron
7 genotype (P  0.045), and the intron 1  intron 7
interaction (P  0.003) were independent predictors of
age at diagnosis. The effects of PPAR genotype were the
same by study center, which did not independently inﬂu-
ence age at diagnosis. Haplotype analysis revealed that
PPAR haplotype signiﬁcantly inﬂuenced age at diagnosis
(P  0.037) (Table 4). Haplotypes 6 and 8, comprising the
intron 1 C- and intron 7 C-alleles with the L162V L162 allele
(haplotype 6, C-L-C) or the V162 allele (haplotype 8,
C-V-C), were associated with an age at diagnosis of 5.86 
2.57 (P  0.02) and 9.98  4.65 (P  0.03) years, respec-
tively, earlier than the common haplotype.
Given the dramatic haplotype effect on age at diagnosis,
the role of PPAR in early-onset type 2 diabetes was
examined. PPAR haplotype frequency was calculated in
subjects stratiﬁed by age of diagnosis of 45 or 
45 years,
based on the previous use of this cutoff age in a linkage
TABLE 1
Characteristics of the study subjects
Age at recruitment (years) 65.4  12.1
Age at diagnosis (years) 54.4  13.0
Duration of diabetes (years) 10.92  9.1
Family history of diabetes (%) 34.0
BMI (kg/m
2) 29.8  5.8
Smoking status (never/former/current) (%) 45.1/38.6/16.3
Glucose (mmol/l) 11.7  5.1
HbA1c (%) 8.0  1.8
SBP (mmHg) 140.6  20.1
DBP (mmHg) 77.3  11.7
Triglycerides (mmol/l) 2.22  1.57
Total cholesterol (mmol/l) 5.02  1.10
LDL cholesterol (mmol/l) 2.81  0.93
HDL cholesterol (mmol/l) 1.31  0.41
Data are means  SD unless otherwise indicated.
TABLE 2
Effect of individual PPAR genotypes on age at diagnosis of type
2 diabetes
Intron 1 A/C
AA 53.1  0.7 (315)
AC 53.2  0.6 (408)
CC 52.0  1.1 (148)
P 0.60
L162V
LL 52.7  0.5 (762)
LV  VV 54.7  1.2 (109)
P 0.13
Intron 7 G/C
GG 52.9  0.6 (574)
GC 53.1  0.7 (268)
CC 51.8  2.7 (29)
P 0.87
Data are means  SE (no. per genotype group). P values were
determined by ANOVA.
TABLE 3
Combined effect of intron 1 A3C and intron 7 G3C variants on
age at diagnosis of type 2 diabetes
Intron 1
A3C
Intron 7 G
C
GG GC CC
AA 54.2  1.0 (199) 54.8  1.0 (117) 58.8  2.7 (18)
AC 54.7  0.8 (269) 55.1  1.0 (148) 45.2  6.4 (6)
CC 54.4  1.2 (130) 49.3  2.9 (20) 39.0  6.9 (5)
Data are means  SE (no. per genotype group).
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frequency was highly signiﬁcantly different between
young-onset and later-onset subjects (P  1.4  10
7),
with haplotype 6 increasing risk of early-onset type 2
diabetes (odds ratio 3.75, 95% CI 1.65–8.56, P  0.002).
Haplotype frequencies were not different between the
entire type 2 diabetes sample and middle-aged U.K. men
without overt type 2 diabetes (P  0.50) but were signiﬁ-
cantly different between middle-aged U.K. men and early-
onset subjects (P  0.024) (Table 4).
We investigated whether PPAR variants inﬂuence the
progression of type 2 diabetes, as estimated by the dura-
tion of diabetes before commencing insulin monotherapy.
In UDACS, carriers and homozygotes of the rare C-allele
progressed to insulin treatment signiﬁcantly earlier than A
allele homozygotes (AA 9.4  1.5 and AC  CC 5.3  1.1
years, P  0.002). The L162V and intron 7 G3C variants
did not inﬂuence duration before insulin therapy. PPAR
genotype did not inﬂuence whether subjects were on an
oral hypoglycemic agent, insulin, or both an oral hypogly-
cemic agent and insulin therapy (not shown). Measures of
progression were not available in EDSC.
Treatment with PPAR activators beneﬁcially alters
plasma lipid proﬁle, and we previously demonstrated that
variation in the PPAR gene inﬂuences plasma lipid levels
in dyslipidemic type 2 diabetic subjects (12). We therefore
examined whether PPAR gene variation inﬂuences
plasma lipid levels in type 2 diabetic subjects, but ob-
served no signiﬁcant association with plasma triglycerides
or LDL, HDL, or total cholesterol concentrations (not
shown).
DISCUSSION
This study demonstrates that variation in the PPAR gene
inﬂuences the onset and progression of type 2 diabetes, in
concurrence with the recent observation that bezaﬁbrate
reduces the incidence and delays the onset of type 2
diabetes (11). Allele and haplotype frequencies were not
different between healthy middle-aged U.K. men and the
type 2 diabetes sample, but haplotype frequency was
different between subjects with age at diagnosis 45 years
and both those with later age at diagnosis and with healthy
middle-aged U.K. men without overt type 2 diabetes,
indicating that PPAR predisposes to early-onset type 2
diabetes. PPAR gene variants inﬂuenced age at diagnosis
in combination and in haplotype analysis. Carriers of the
intron 1 and 7 rare C-alleles had a dramatically younger
age at diagnosis, an effect conﬁrmed in haplotype analysis,
in which haplotypes 6 and 8, comprising the intron 1 C-
and intron 7 C-alleles with the L162 or V162 alleles,
respectively, were associated with an age at diagnosis 5.8
and 10.0 years earlier than the common haplotype. Ge-
nome scans have identiﬁed several loci linked to age at
diagnosis (19,20), one of which maps in a subset of
families with age at diagnosis 	45 years to chromosome
22q11 (19), 28 Mb centromeric to the PPAR gene.
The PPAR intron 1 genotype was also associated with
a more rapid progression to insulin monotherapy, suggest-
ing that PPAR inﬂuences the rate of development of
insulin resistance and/or progression to -cell failure.
PPAR is expressed in liver, skeletal muscle, and pancreas
(5) and could therefore affect the disease process at
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584 DIABETES, VOL. 54, FEBRUARY 2005multiple levels. In rodents, PPAR activators lowered fasting
plasma triglycerides, and free fatty acids, as well as lowered
visceral adiposity and muscle and hepatic steatosis, resulting
in improved hepatic and muscle insulin sensitivity and im-
proved pancreatic -cell function. Genetically determined
reduced PPAR levels may inﬂuence any of the above-
mentioned factors. We did not observe association between
PPAR variation and plasma triglyceride levels (fasting tri-
glyceride levels were not available for all subjects), thus
decreasing the power to observe an effect. Studies that
directly assess the impact of PPAR gene variants on levels
of intramuscular and intrahepatic triglycerides, whole-body
glucose uptake, and -cell function will elucidate the mech-
anisms underlying the observed effects.
The PPAR genotype inﬂuences the risk of coronary
artery disease (15), and it is conceivable that it could
increase the likelihood of subjects presenting with heart
disease and subsequently being diagnosed with type 2
diabetes, thus confounding the current study. The pres-
ence of cardiovascular disease was in fact associated with
later age at diagnosis (absence 53.4  0.5 years, presence
56.5  0.7 years, P  0.001) and did not inﬂuence the effect
of PPAR genotype on age at diagnosis, indicating that
these data are not confounded by cardiovascular disease.
The differences between UDACS and EDSC in BMI, mea-
sures of glycemic control, blood pressure, and plasma
lipids did not confound the effect of PPAR haplotype on
age at diagnosis.
Mechanistically, several lines of evidence lead us to
speculate that the intron 1 C- and intron 7 C-alleles mark a
haplotype with reduced PPAR gene expression. First, in
previous studies, the intron 7 C-allele shows opposing
effects to the V162 allele (14,15), which encodes a more
active PPAR in vitro (12). Furthermore, the intron 7
C-allele is associated with reduced response to fenoﬁbrate
in the DAIS (Diabetes Atherosclerosis Intervention Study)
(21). Finally, PPAR activators delay onset of type 2
diabetes in humans (11) and rats (10), indicating that
increased PPAR activity protects against the onset of
type 2 diabetes.
PPAR interacts with several genes that inﬂuence type 2
diabetes. Hepatic PPAR gene expression is regulated by
hepatocyte nuclear factor 4 (22), a closely related mem-
ber of the nuclear hormone receptor superfamily that is
associated with risk of type 2 diabetes (23). Additionally,
genetic variation in PPAR coactivator-1, which also co-
activates PPAR, inﬂuences the insulin secretory response
in Pima Indians (24). The retinoid X receptor , with which
PPAR forms heterodimers, also inﬂuences insulin resis-
tance (25). It will be interesting to examine interaction
between PPAR and hepatocyte nuclear factor 4, PPAR
coactivator-1, and retinoid X receptor  gene variants in
subsequent studies.
In summary, we demonstrate that PPAR gene variation
inﬂuences the onset and progression of type 2 diabetes in
human subjects. The mechanisms underlying these effects
remain unclear and warrant future investigation.
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